Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493064 · ClinicalTrials.gov registry record · Phase 2
To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
A Phase 2 study, sponsored by Palo Alto Medical Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00493064: Completed Phase 2 study, sponsored by Palo Alto Medical Foundation.
NCT00493064 is a Phase 2 study that has completed, run by Palo Alto Medical Foundation. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493064, a Phase 2 study, has completed, sponsored by Palo Alto Medical Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Niacin, a B vitamin, may act as a vasodilator to encourage earlier formation of collateral blood vessels that may serve to bypass the obstructed vein in the eye. The topical steroid eye drops are aimed at reducing swelling in the retina, until the collateral vessels have a chance to develop.
Primary Outcome
improvement with combination of niacin and topical prednisolone acetate
Interventions
- DRUG Nicotinic acid
- DRUG Prednisolone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
What the finished NCT00493064 record still lists
NCT00493064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Nicotinic acid is the first listed.
NCT00493064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00493064 about?
NCT00493064 is a clinical study titled "To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions". The purpose of this study is to determine whether Niacin, a B vitamin, may act as a vasodilator to encourage earlier formation of collateral blood vessels that may serve to bypass the obstructed vein in the eye. The topical steroid eye drops are aimed at reducing swelling in the retina, until the co...
What is the current status of trial NCT00493064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2006-10. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00493064?
The interventions under investigation include: Nicotinic acid (DRUG), Prednisolone acetate (DRUG).
Who is sponsoring clinical trial NCT00493064?
This trial is sponsored by Palo Alto Medical Foundation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00493064's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia